4//SEC Filing
JOHNSON KENNETH ERLAND 4
Accession 0000899243-21-039246
CIK 0001346302other
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 5:33 PM ET
Size
23.2 KB
Accession
0000899243-21-039246
Insider Transaction Report
Form 4
JOHNSON KENNETH ERLAND
See Remarks
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-10-05−33,686→ 0 totalExercise: $1.55Exp: 2027-02-04→ Common Stock (33,686 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-10-05−39,633→ 0 totalExercise: $5.93Exp: 2028-01-31→ Common Stock (39,633 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-10-05−32,500→ 0 totalExercise: $13.88Exp: 2029-01-31→ Common Stock (32,500 underlying) - Disposition to Issuer
Common Stock
2021-10-05−11,250→ 78,333 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-10-05−5,280→ 0 totalExercise: $1.55Exp: 2027-06-12→ Common Stock (5,280 underlying) - Disposition to Issuer
Common Stock
2021-10-05−78,333→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-10-05−21,401→ 0 totalExercise: $19.00Exp: 2028-10-04→ Common Stock (21,401 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-10-05−100,000→ 0 totalExercise: $3.94Exp: 2030-08-14→ Common Stock (100,000 underlying)
Footnotes (8)
- [F1]On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
- [F2](Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax.
- [F3]Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time.
- [F4]At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
- [F5]These options are fully vested as of the date hereof.
- [F6]25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
- [F7]50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date.
- [F8]These options are early exercisable.
Documents
Issuer
XERIS PHARMACEUTICALS INC
CIK 0001346302
Entity typeother
Related Parties
1- filerCIK 0001743774
Filing Metadata
- Form type
- 4
- Filed
- Oct 4, 8:00 PM ET
- Accepted
- Oct 5, 5:33 PM ET
- Size
- 23.2 KB